Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — JP Morgan Healthcare Conference 2024
28 slides from Jb Chemicals & Pharmaceuticals's conference presentation, Jan 9, 2024
Slide 1: NSE filing cover letter
January 9, 2024 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Presentation Enclosed please find the presentation proposed to be made by the Company at the JP Mo
Slide 2: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference Nikhil Chopra, CEO & Wholetime Director– JB PHARMA January 2024
Slide 3: Disclaimer
DISCLAIMER No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Rich Legacy, Promising Future
RICH LEGACY, PROMISING FUTURE Foundation laid by late Mr. J.B. Leading private equity Forayed into the Mody by Made a strategic firm Kohlberg Kravis cardiac segment Launch of new identity incorporating J. Received first FDA investment in a company Roberts & Co. Inc. (KKR), with the Iconic product B.
Slide 5: Our Purpose & Values
OUR PURPOSE & VALUES WE ARE, AND ALWAYS WILL BE OUR PURPOSE OUR CORE VALUES is to contribute to healthcare, support healthcare providers and SIMPLICITY RELIABILITY enrich patients’ lives, creating significant and sustainable value for in our in our our key stakeholders. actions AGILITY relationships
Slide 6: Corporate Snapshot
CORPORATE SNAPSHOT A consistent track record in key markets/businesses with a ‘best-in-class’ execution rigor and incremental innovation mindset resonating with our purpose of ‘Enriching Patients’ Lives’ 47 8 40+ Top 5 Top 25 Years of operations Multi-dosage formulation Regulated/ semi- Global manuf
Slide 7: Our Aspiration
Our Aspiration: INR 50+ Bn Revenue Organisation by FY27
Slide 8: In FY23, we delivered strong progress on our strategic priorities for FY27
In FY23, we delivered strong progress on our strategic priorities for FY27 FY27 Targets YTD FY24 progress Excellence in Domestic Business ✓ Ranked in IPM Top #25 companies Ranked in top #15 IPM positions with 60% IPM* rank improvement with scale contribution to total revenue. Productivity ✓ ~60% con
Slide 9: Financial Delivery: A Successful H1 FY2024
FINANCIAL DELIVERY: A SUCCESSFUL H1 FY2024 The business delivered a healthy blend of domestic and international business growth, with expansion in domestic business and sustained traction in the CDMO** segment Net Income ** Contract Development and Manufacturing Organisation Good People for Good Hea
Slide 10: Strong Balance Sheet & Free Cash Flow
STRONG BALANCE SHEET & FREE CASH FLOW Strong customer focus, continued rigor on execution and cash generation initiatives have improved financial metrics. JB Pharma approaching zero net debt position as on Dec 31, 2023 Revenue (INR Mn) Net Income (INR Mn) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 42% 2
Slide 11: Stock Price Performance
STOCK PRICE PERFORMANCE Good People for Good Health 08
Slide 12: Key Pillars for Growth
oS \@ Key Pillars for Growth ® ~
Slide 13: Domestic Business
Domestic Business Driving Growth, Gaining Momentum
Slide 14: Domestic Business: Strong Growth over the Years
DOMESTIC BUSINESS Strong Growth over the Years… FASTEST GROWING IN TOP 25 IPM* COMPANIES DOMESTIC BUSINESS REVENUE (INR Millions) 16400 CAGR - 27% 11730 Leadership position Market-Beating growth in the covered markets 8920 40% 7970 18% Vs IPM growth of 10% (IQVIA MAT Sept’23 data) 35% + market share
Slide 15: Strong Prescription Depth & Prescriber Connect Across Specialties
Strong Prescription Depth & Prescriber Connect Across Specialties JB Pharma : 15th Largest Company By Prescriptions In IPM* JB Pharma Total Prescriptions JB Pharma Specialty Coverage (in millions) 15% 15680 128,000 8,000 Physicians Cardiologists 35% 12310 46,000 3,400 9290 dolor sit amet Lorem ipsum
Slide 16: Making Big Brands Bigger
Making Big Brands Bigger CONSISTENT RANK IMPROVEMENT BUILDING STRONGER BRAND FOR TOP 6 BRANDS FRANCHISES MAT Sept’22 MAT Sept’23 MAT Sept’22 Rank MAT Sept’23 Rank Value Sales* Value Sales* TM T M TC 2920 3580 #48 #35 CILACAR INR 3900 mn INR 5800 mn METROGYL 3140 3550 #41 #37 IQVIA MAT Sept’21 IQVIA
Slide 17: Strong Growth Led By Chronic Business; Outperforming The Industry
Strong Growth Led By Chronic Business; Outperforming The Industry JB Pharma among the Top 10 Cardiology players in the India Pharma Market 25% JB Pharma Total Prescriptions As per IQVIA MAT Sept’23 data vs MAT Sept’22 numbers, JB Pharma’s Chronic segment grew JB Pharma’s 25% while overall industry C
Slide 18: Growth Further Fuelled by Acquisitions
GROWTH FURTHER FUELLED BY ACQUISITIONS Successfully completed 5 acquisitions from FY22 to FY24 deploying $200 Mn Stellar performance in all the acquired portfolios 01 02 03 04 05 Probiotic Portfolio Azmarda Paedia Portfolio Razel Franchise Ophthalmology Portfolio • Marked JB’s entry into the high •
Slide 19: International Business
International Business Delivering Value in Challenging Times
Slide 20: International Business: Distinct Operating Models Across Geographies
International Business: Distinct Operating Models Across Geographies Branded Generics Contract Development and API (Formulations) Manufacturing (CDMO) • Direct Presence in Russia and • Among the top 5 manufacturers of • Dedicated manufacturing facility in South Africa Lozenges globally Panoli, India
Slide 21: International Business: Sustained Growth across all Businesses
International Business: Sustained Growth across all Businesses International Export Formulations CDMO API CAGR 13% CAGR 32% CAGR 9% 910 940 10090 4060 860 8920 720 8170 6960 2530 2240 1760 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 As a percentage of overall International 67% 27% 6%
Slide 22: CDMO Business: A Key Focus Area
Besides Domestic Business, The CDMO Business is One Of The Key Focus Areas For The Organization Consistent Growth in the CDMO Business 60% Coverage into semi regulated/other YoY growth in FY23 RoW markets Projects focused on Experience in working with lozenges, syrups, tablets, marquee global pharma
Slide 23: Innovative Technologies
INNOVATIVE TECHNOLOGIES Our experience of 2 decades in manufacturing lozenges has led us Our lozenges plant to export to 40+ countries and be the in Gujarat, India is partners of choice for leading MNCs. fully automated, with state-of-the- art machines. JB is amongst the handful of companies in Indi
Slide 24: Our Manufacturing Capabilities
OUR MANUFACTURING CAPABILITIES 8 Good People for Good Health 18
Slide 25: Our People Are Our Most Valuable Assets
OUR PEOPLE ARE OUR MOST VALUABLE ASSETS Grooming Capability Employee Future Leaders Building Well-being DE&I • Functional and Leadership • Our 2500+strong manufacturing • Enabling employees to focus • In Q2 FY24, an organisation development programs in & R&D teams are nurtured by on holistic well-be
Slide 26: Our Sustainability Progress So Far - FY23
OUR SUSTAINABILITY PROGRESS SO FAR - FY23 ENERGY WATER • 8464.89GJ derived from renewable sources of energy • 40KL of water treated daily through ETP and re- • Energy intensity decreased by 6.7% while GHG used intensity decreased by 19% compared to last year • All sites are Zero Liquid Discharge EMI
Slide 27: JB Pharma – Looking Ahead
JB Pharma – Looking Ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform market growth Continued growth momentum in International business driven by Strong delivery in CDMO business aided by new launches Big bra
Slide 28: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you 0090 www.jbpharma.com
J.B. Chemicals & Pharmaceuticals — JP Morgan Healthcare Conference 2024 on 6ix